Skip to main content
. 2008 Mar;19(3):547–558. doi: 10.1681/ASN.2007040469

Table 3.

Lung inflammatory genes that are significantly affected during severe AKI

Gene Title Gene Symbol Fold Change
PubMatrix
6 h 36 h Lung Inflammation
Significant at 6-h timepoint
    chemokine (C-C motif) ligand 9 Ccl9 4.11 1.86b 0
    leukocyte immunoglobulin-like receptor B3 Lilrb3 3.63 1.80 0
    thrombospondin 1 Thbs1 3.48 1.28 3
    CD14 antigen Cd14 3.21 1.71 30
    CCAAT/enhancer binding protein (C/EBP), beta Cebpb 2.99 1.98 1
    phospholipase A2, group VII Pla2g7 2.91 5.60 0
    Fc receptor, IgE, high affinity I, gamma Fcer1g 2.81 2.97 0
    serum amyloid A 2 Saa2 2.59 1.32 12
    fatty acid binding protein 4, adipocytea Fabp4 −2.51 −2.44 0
    roundabout homolog 1 Robo1 −2.69 −1.45 0
Significant at both timepoints
    serum amyloid A 3 Saa3 15.99 6.42 3
    chemokine (C-X-C motif) ligand 2 Cxcl2 14.67 2.69 17
    IL-1 receptor, type II Il1r2 5.88 11.34 0
    inhibin beta-B Inhbb 6.93 3.70 0
    serum amyloid A 1 Saa1 5.91 2.45 9
    suppressor of cytokine signaling 3 Socs3 5.47 2.41 0
    chemokine orphan receptor 1 Cmkor1 3.57 3.71 1
    chemokine (C-C motif) receptor 1 Ccr1 2.73 3.76 2
    formyl peptide receptor, related sequence 2 Fpr-rs2 2.76 3.72 0
    interleukin 4 receptor, alpha Il4ra 2.42 3.87 4
Significant at 36-h timepoint
    serine/cysteine peptidase inhibitor, clade A 3N Serpina3n 2.03 7.72 0
    lipocalin 2 Lcn2 1.64 5.81 3
    FMS-like tyrosine kinase 1 Flt1 1.65 4.59 0
    arachidonate 5-lipoxygenase activating protein Alox5ap 2.29 3.80 0
    S100 calcium binding protein A9 S100a9 1.55 3.57 6
    chemokine (C-C motif) ligand 6 Ccl6 2.30 3.09 0
    signal transducer and activator of transcription 3 Stat3 1.99 3.04 9
    peptidoglycan recognition protein 1 Pglyrp1 1.37 2.83 0
    IL-1 receptor-like 1 Il1rl1 −1.20 −2.70 3
    chemokine (C-X-C motif) ligand 12 Cxcl12 −1.82 −3.57 2

Significance criteria: 2.38 fold change and 2% false discovery rate (see Concise Methods).

a

Significantly affected after 30 min of ischemia (Figure 5A);

b

failed significance testing.

HHS Vulnerability Disclosure